Skip to content

Our mission is to develop the next generation diagnostics using single-cell analysis to save lives

Path

About us

Extracting knowledge from single-cell data to save millions of lives
A new and emerging type of analytical devices produce rich data-sets by measuring hundreds of parameters from millions of individual cells. The resulting single-cell data holds the information needed for early disease detection, but it requires sophisticated and innovative computational approaches in order to extract the relevant information.
We address this problem by developing artificial intelligence (AI) software for single-cell data analysis. The underlying algorithms allow us to associate patterns in single-cell data with disease status, similar to how state-of-the-art methods for object recognition associate pixel patterns with objects. We provide a software solution (ScaiVision), wrapping our AI technology for R&D customers from academia, pharmaceutical and clinics.

Vision

We expose complex diseases with high precision at an early stage to improve and save lives.
values

Our Team

LinkedInCreated with Sketch.

Dr. Peter Nestorov

Founder & Chief Executive Officer

Peter holds a PhD in Genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen. He has been working in the emerging single-cell analysis market since 2015 and this gave him the inspiration to start Scailyte as co-founder and CEO in 2017.

Read bio

Dr. Vijay Tiwari

Director Biomarker Discovery

Vijay  gained a PhD in Genetics from Uppsala University, Sweden and following training at the Johns Hopkins University, USA and Friedrich Miescher Institute in Basel, Switzerland, he has led a biomedical research group at the Institute of Molecular Biology in Germany before joining Scailyte in 2018.

Read bio
LinkedInCreated with Sketch.

Dr. Sarah Carl

Director Data Science

Sarah holds a PhD in Genetics from the University of Cambridge. She worked as a bioinformatician at the Friedrich Miescher Institute in Basel, Switzerland, for four years before joining Scailyte. Sarah joined Scailyte as a data scientist in 2018 and has been recently promoted to become Director of Data Science.

Read bio
LinkedInCreated with Sketch.

Stefan Almestrand

LinkedInCreated with Sketch.

Director Corporate Development

Stefan has a Master’s degree in Chemical and Biotech Engineering. He has 10+ years experience holding various European and Global commercial roles in diagnostic and pharmaceutical companies. Stefan joined Scailyte in 2018

Read bio

Anna Dimitrova, ACCA

Director Finance & Operations

Anna is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Previously, she worked as a finance manager in a fast growing company, auditor in KPMG and business consultant in PwC. Anna joined the Scailyte team in 2018.

Read bio
LinkedInCreated with Sketch.

Join the Scailyte team
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com

Become part of something greater

In our mission to discover complex diseases patterns through single-cell data, we are looking for bright, passionate, and dedicated individuals who share our values of dream big, make it happen and strive for qiality to join our growing energetic & fun team. We offer flexible working schedule and home-office options.

Join the Scailyte team
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com

Recent News

ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.

As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,

Read more

Recent News

Scailyte closed today their pre-series A financing with Investiere as an additional investor

Read more

Recent News

Interview with Scailyte’s CEO Peter Nestorov

In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO

Read more

Recent News

Interview with Scailyte Founder Prof. Dr. Manfred Claassen

In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri

Read more

Recent News

Scailyte: simplifying difficult diagnoses

Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare

Read more

Recent News

Scailyte among The Spinoff Prize finalists

Scailyte is among the ten selected young science-based university spinoff companies that showcase th

Read more

Recent News

Scailyte closes pre-series A financing round

Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to furthe

Read more

Recent News

Scailyte and CHU Rennes partnership for identifying Covid-19 patients

Scailyte and CHU Rennes have made an initial discovery of a single-cell

Read more

Recent News

01 /04

ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.

As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,

Read more

Scailyte closed today their pre-series A financing with Investiere as an additional investor

Read more

Recent News

02 /04

Interview with Scailyte’s CEO Peter Nestorov

In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO

Read more

Interview with Scailyte Founder Prof. Dr. Manfred Claassen

In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri

Read more

Recent News

03 /04

Scailyte: simplifying difficult diagnoses

Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare

Read more

Scailyte among The Spinoff Prize finalists

Scailyte is among the ten selected young science-based university spinoff companies that showcase th

Read more

Recent News

04 /04

Scailyte closes pre-series A financing round

Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to furthe

Read more

Scailyte and CHU Rennes partnership for identifying Covid-19 patients

Scailyte and CHU Rennes have made an initial discovery of a single-cell

Read more

Recent News

Dr. Peter Nestorov

Founder & Chief Executive Officer

Co-founder and Chief Executive Officer of Scailyte. He holds a PhD in genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen.

During his PhD work, Dr. Nestorov pioneered the development and application of methods for single-cell analysis, which sparked his passion for this technology. In 2015, Dr. Nestorov joined Witec AG as Sales Specialist for single-cell and genomics technologies and successfully introduced the first commercial devices for single-cell analysis on the Swiss Life Science market. The interaction with biomedical researchers and the technological insight inspired Dr. Nestorov to start Scailyte and unlock the full clinical potential of single-cell data.

Mobile Menu Closed

Dr. Vijay Tiwari

Director Biomarker Discovery

Is the Lead of Biomarker Discovery at Scailyte. Dr.Tiwari gained a PhD in Genetics from Uppsala University, Sweden. After his PhD he moved to the USA to work as a post-doc in the field of Cancer Research at the Johns Hopkins University School of Medicine followed by Switzerland to work further in the field of Stem Cell Biology and Neurobiology at the Friedrich Miescher Institute for Biomedical Research, Basel. Before joining Scailyte Dr. Tiwari was a research group leader at Institute for Molecular Biology in Mainz, Germany.
Dr. Tiwari is leading the biomarker discovery division, overseeing Scailyte’s clinical research programmes.

Mobile Menu Closed

Dr. Sarah Carl

Lead Data Scientist
is managing the Data Science division of Scailyte. She holds a PhD in Genetics and a Master’s degree in Developmental Biology from the University of Cambridge. Before joining Scailyte she was a post-doc and bioinformatician at the Friedrich Miescher Institute for Biomedical Research in Basel. At Scailyte she is leading the development of new applications and features of the internal data analysis platform, ScaiVision, and the data analysis of the clinical programmes.
Mobile Menu Closed

Stefan Almestrand

Director Clinical Development & Commercialization
Is Director of Corporate Development. He obtained a Master’s degree in Chemical and Biotech Engineering from the Royal Institute of Technology, Sweden. He started his career as a Project Manager at the Karolinska Institute in Sweden following a commercial career in business and medical affairs at various life Science, pharmaceutical and biotech companies such as Thermo Fisher Scientific, AstraZeneca and Fluidigm corporation. As the corporate development director at Scailyte, he works on the business strategy and commercial partnerships of the company.
Mobile Menu Closed

Anna Dimitrova, ACCA

Director Finance & Ops
Is the Director of Finance and Operations at Scailyte. She is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Before joining Scailyte she worked as Senior Audit Assistant at KPMG, Senior Business Consultant at PwC and as Finance Manager in a fast growing company in Bulgaria. At Scailyte she leads the finance, administration and internal operations of the company.
Mobile Menu Closed

Prof. Dr. Manfred Claassen

Founder & Chief Scientific Advisor AI & Single-Cell Analysis
Co-founder and Chief Scientific Advisor at Scailyte. He holds degrees in both Biochemistry and Computer Science from the University of Tübingen and a PhD in the design and validation of proteome measurements from the ETH Zurich. He continued his academic path as a postdoctoral researcher at Stanford University’s Artificial Intelligence Lab focusing on research in machine learning for high dimensional single-cell biology, he moved back to Switzerland as an Assistant Professor at the ETH. During this time, the idea of establishing a company specialising in digital healthcare was conceived. Dr. Claassen was instrumental in conceptualizing the new company. He is now professor for clinical bioinformatics at the University of Tübingen, Germany in parallel with his role as scientific consultant for Scailyte.
Mobile Menu Closed

Prof. Dr. Emmanuella Guenova

Clinical Advisor CTCL & Immunology
is a dermatologist, specialist in cutaneous lymphoma and laboratory diagnostics of skin diseases, and appointed professor at the Faculty of Biology and Medicine of the University of Lausanne. She is a senior physician-scientist, leading the specialized cutaneous lymphoma clinic at the Department of Dermatology of the Lausanne University Hospital (CHUV). Prof. Guenova is supporting Scailyte as a clinical advisor and principal investigator in our clinical development program for cutaneous T-cell lymphoma.
Mobile Menu Closed

Dr. Michael Stadler

received training in immunology and bioinformatics from the Universities of Lausanne and Geneva. He is a scientific advisor supporting Scailyte’s with the development of our data analytics platform. After postdoctoral studies in Bern and at the Massachusetts Institute of Technology (MIT), he joined the Friedrich Miescher Institute for Biomedical Research (FMI) Basel, where he is a staff scientist and leads the computational biology group.
Mobile Menu Closed

Pascal Winnen

CEO Hemex AG & Scailyte Board of Directors

Pascal is a co-founder and the CEO of HEMEX, a pharmaceutical, biotech and medical device consulting firm with offices in Switzerland, Germany and the USA. He holds a bachelor’s degree in Telecommunication Technologies from the University of Leuven (Belgium) and a master’s degree in Clinical Research from the Donau University in Krems (Austria). Pascal worked in various positions in the pharmaceutical and medtech industry.

From 2011 to 2015, Pascal worked for Finox Biotech, bringing one of the first biosimilar fertility treatments to the market in the EU and leading to the successful acquisition by Gedeon Richter for CHF 190 million. With his consulting firm HEMEX, Pascal has invested in multiple innovative life science startups, where he also advises on regulatory, clinical and marketing strategies, either as a senior consultant or as a board member.

Mobile Menu Closed

Dominique Mégret

Head of Swisscom Ventures & Scailyte Board of Directors
Dominique Mégret is head of Swisscom Ventures, which he started in 2007. He joined Swisscom in 2002 as head of the Group Strategy unit. Previously, Dominique Mégret was an entrepreneur in the United Kingdom, a strategy consultant in the European telecom industry and country manager for an IT company in Germany. He currently serves on the boards of Scailyte AG and Bloom SA. He is also an observer on the boards of Sophia Genetics and AVA Women.
Mobile Menu Closed